RR-M08

RR-M08 is a chimeric antigen receptor macrophage (CAR-M) cell therapy being developed by RocRock Biotechnology for the treatment of pulmonary fibrosis. As a CAR-M therapy, it involves genetically engineering macrophages to express a chimeric antigen receptor (CAR) that targets specific antigens associated with fibrotic lung tissue. This approach leverages the natural phagocytic and tissue-remodeling capabilities of macrophages to potentially clear fibrotic cells or modulate the inflammatory environment in the lungs. The specific biological target for RR-M08 has not been publicly disclosed by the company. The candidate is currently in the preclinical stage of development.